open access

Vol 57, Supp. A (2006)
Original paper
Submitted: 2013-02-15
Published online: 2006-09-25
Get Citation

SNP polymorphism of LGALS3BP gene in patients with benign and malignant thyroid tumours

Tadeusz Łukieńczuk, Krzysztof Kaliszewski, Magdalena Żołędziewska, Anna Jonkisz, Grażyna Dmochowska, Mirosław Dobrut, Jacek Rogoliński, Tadeusz Dobosz

open access

Vol 57, Supp. A (2006)
Original Paper
Submitted: 2013-02-15
Published online: 2006-09-25

Abstract

Introduction: The aim of the study was estimation of occurrence of SNP (single nucleotide polymorphism) sites in LGALS3BP gene in patients with benign and malignant thyroid tumors and analysis of correlation between their frequency and the histological type of thyroid lesions.
Material and methods: The studied group consisted of 58 patients, 24 with papillary thyroid carcinomas, 19 with nodular goiters and 15 with follicular adenomas. Control group included 180 healthy volunteers. Four different SNP polymorphisms were analysed in PCR products using the SNaPshot test, on genetic analyser ABI Prism 310; these can be found in NCBI database under rs numbers: 1803938 (a/g), 11024 (g/c), 1801463 (a/c) and 1131516 (c/t).
Results: In all patients analysis of SNP sites revealed: lack of polymorphism in a/g rs 18039380; polymorphism identical to database in g/c rs 11024 and polymorphism different from database in a/g rs 1801463 and c/g rs 131516. There were no significant differences between patients with thyroid lesions and group of healthy controls.
Conclusion: Single nucleotide polymorphism (SNP) of LGALS3BP gene (found in NCBI) database are not characteristic for papillary thyroid cancer, follicular adenomas and nodular goiter.

Abstract

Introduction: The aim of the study was estimation of occurrence of SNP (single nucleotide polymorphism) sites in LGALS3BP gene in patients with benign and malignant thyroid tumors and analysis of correlation between their frequency and the histological type of thyroid lesions.
Material and methods: The studied group consisted of 58 patients, 24 with papillary thyroid carcinomas, 19 with nodular goiters and 15 with follicular adenomas. Control group included 180 healthy volunteers. Four different SNP polymorphisms were analysed in PCR products using the SNaPshot test, on genetic analyser ABI Prism 310; these can be found in NCBI database under rs numbers: 1803938 (a/g), 11024 (g/c), 1801463 (a/c) and 1131516 (c/t).
Results: In all patients analysis of SNP sites revealed: lack of polymorphism in a/g rs 18039380; polymorphism identical to database in g/c rs 11024 and polymorphism different from database in a/g rs 1801463 and c/g rs 131516. There were no significant differences between patients with thyroid lesions and group of healthy controls.
Conclusion: Single nucleotide polymorphism (SNP) of LGALS3BP gene (found in NCBI) database are not characteristic for papillary thyroid cancer, follicular adenomas and nodular goiter.
Get Citation

Keywords

single nucleotide polymorphism (SNP); LGALS3BP gene; nodular goiter; follicular adenomas; thyroid cancer

About this article
Title

SNP polymorphism of LGALS3BP gene in patients with benign and malignant thyroid tumours

Journal

Endokrynologia Polska

Issue

Vol 57, Supp. A (2006)

Article type

Original paper

Pages

45-52

Published online

2006-09-25

Page views

781

Article views/downloads

1144

Keywords

single nucleotide polymorphism (SNP)
LGALS3BP gene
nodular goiter
follicular adenomas
thyroid cancer

Authors

Tadeusz Łukieńczuk
Krzysztof Kaliszewski
Magdalena Żołędziewska
Anna Jonkisz
Grażyna Dmochowska
Mirosław Dobrut
Jacek Rogoliński
Tadeusz Dobosz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl